# Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

> **NCT00566098** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** MILs
- **DRUG:** Melphalan
- **BIOLOGICAL:** PCV13

## Key facts

- **NCT ID:** NCT00566098
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2014-06
- **Final completion:** 2018-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566098, "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00566098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*